Abstracts

Small Molecule GAL-201 under development for oral AD treatment: Modulation of Aβ aggregation directly influences synaptic plasticity and also affects neuroinflammation

The amyloid beta aggregation modulator GAL-201 is under development for oral AD treatment: Cognitive improvement in a transgenic AD model

GAL-101 prevents β-amyloid induced membrane depolarization in two different types of retinal cells. Poster presentation

Sustained neuroprotective effect of novel Aβ aggregation modulator GAL-101 shown in dry AMD and glaucoma models with transient peak concentrations using eye drops.